Seaport Therapeutics, Inc. Common Stock (SPTX) Stock
NYSE · SPTX
21.12
Fundamentals
Market cap
$1.15B
Price / Earnings ratio
-15.3x
Price / Sales ratio
N/A
Price / Book ratio
2.7x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for depression, anxiety, and other neuropsychiatric disorders. The company’s approach centers on targeting clinically validated mechanisms with established efficacy and safety profiles, while addressing historical limitations such as high first-pass metabolism, low bioavailability, and adverse side effects.
SectorHealthcare
IndustryBiotechnology
Employees58
CEOMs. Daphne Zohar
IPO DateMay 1, 2026
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Steven M. Paul M.D. | Founder & Non-Employee Chair of the Board | 1951 |
| Ms. Daphne Zohar | Founder, CEO, President & Director | 1971 |
| Dr. Michael Cunyuan Chen Ph.D. | Co-Founder & Chief Scientific Officer | 1984 |
| Dr. Antony Loebel M.D. | Chief Medical Officer & President of Clinical Development | 1961 |
| Ms. Lauren A. White M.B.A. | Chief Financial Officer | 1979 |
| Ms. Lana Gladstein J.D. | General Counsel | 1976 |
Fundamentals
Valuation
Market cap$1.15B
Price-to-sales ratioN/A
Price-to-book value2.71
Price-earnings ratio-15.30
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-31.54
Income Statement
Average volume248,336
EBITDA$-72.70M
1 year high (52w)$28.38
1 year low (52w)$14.85
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



